Tuesday, October 28, 2025 10/28/2025

Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and Immunotherapy

Award Number: UH3CA247605
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and Immunotherapy - The proposed project is in the field of thoracic oncology. Lung cancer patients that get treated with radiotherapy and immunotherapy are at risk of developing serious lung side-effects, and in particular, pneumonitis. Pneumonitis results in cough, shortness of breath, and can be fatal. Pneumonitis, is a serious, overlapping toxicity that can results as a function of both radiotherapy and immunotherapy. Pneumonitis has a significant impact on patient quality of life and limits the aggressive combinations of therapies that can be evaluated in clinical trials. Strategies are needed that can reduce pneumonitis rates for patients treated with aggressive combinations of radiotherapy and immunotherapy in clinical trials. A novel lung function imaging modality has been developed that uses data acquired as part of routine clinical care for lung cancer patients along with software techniques to innovatively calculate lung function maps. The novel lung function imaging modality has been incorporated into radiotherapy through a personalized, functional avoidance radiation treatment paradigm. The idea of functional avoidance is to design radiation treatment plans that reduce dose to functional portions of the lung with the hypothesis that reduced dose to functional lung will lead to decreased side-effects from treatment and improved quality of life. Imaging-based functional avoidance provides a promising method for significantly reducing toxicity for lung cancer patients who get treated with combinations of radiotherapy and immunotherapy. The problem is that the novel lung function imaging methods have not been developed and evaluated with immunotherapy added to the treatment paradigm. The purpose of our project is to develop novel methods that enable the evaluation of imaging-based functional avoidance for patients enrolled in radiotherapy and immunotherapy clinical trials. Our study will develop methods that provide a complete picture of lung function (perfusion imaging in addition to ventilation), evaluate the most stable and clinically relevant form of lung function imaging, and perform a sensitivity analysis of how various functional parameters effect radiation treatment plans for patients treated with radiotherapy and immunotherapy. Our study will use data from 4 clinical trials to evaluate whether the proposed imaging framework can reduce toxicity for lung cancer patients in the setting of immunotherapy added to the treatment paradigm. More aggressive combinations of radiotherapy and immunotherapy are going to continue to evolve and be investigated in clinical trials. Pulmonary toxicity will be a serious clinical limitation for these studies. Our project proposes a convenient, inexpensive imaging modality to reduce toxicity and has the potential to significantly improve quality of life of lung cancer patients treated with radiotherapy and immunotherapy. The impact of our imaging framework is that it can 1) reduce treatment-related side-effects for patients treated with radiotherapy and immunotherapy and 2) enable the investigation of more-aggressive radiotherapy and immunotherapy treatment approaches for lung cancer patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $420,407 )
2025	2025	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	5	8/28/2025	NON-COMPETING CONTINUATION	$420,407
														Subtotal = $420,407

Issue Date FY: 2024 ( Subtotal = $400,008 )
2024	2024	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	001	4	9/9/2024	NON-COMPETING CONTINUATION	$223,430
2024	2023	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	3	2/9/2024	EXTENSION WITH OR WITHOUT FUNDS	$176,578
														Subtotal = $400,008

Issue Date FY: 2023 ( Subtotal = $414,944 )
2023	2023	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	3	9/8/2023	EXTENSION WITH OR WITHOUT FUNDS	$414,944
														Subtotal = $414,944

Grand Total All Awards = $1,235,359

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and Immunotherapy

Award Number: UH3CA247605

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer